English (UK)
中文版Luye pharma 
Dr Fang Zhang
Senior Business Development ManagerMs. Jieyun Hao
HR managerMr. Jibo Wang
RA specialistMira Life Science Ventures 
Mira Life Science Ventures was established to change the paradigm for investment, incubation and development of new disruptive and game-changing technologies in the life sciences. Mira LSV will invest in medical devices, therapeutics, diagnostics, enabling technologies and digital healthcare. Mira LSV will focus its efforts in areas of significant unmet medical needs such as cancer, neurological diseases, infectious disease, autoimmune disease, inflammatory diseases, personalized medicine, cardiovascular disease and renal diseases.
In order to change the venture investment paradigm, Mira LSV was formed to break out of the traditional venture model and move to a more flexible, nimble and shareholder-centric model to accelerate development of these break-through products and technologies and bring them to patients. Mira LSV’s highly flexible business structure, broad and diverse access to deal-flow and highly experienced management team will ensure we have a significant positive impact on our healthcare system.
Mr. Mel Rothberg
ChairmanMSQ Ventures
Mr. Estigarribia Marc
MDQilu Pharmaceutical North America
Qilu pharmaceutical has always been sticking to the innovative development strategy. Guided by the market demand and the product innovation, Qilu has established extensive cooperation with domestic and foreign partners on a series of R&D projects. Qilu pays high attention to the introduction and cultivation of talents and has built a highly qualified R&D team with professional and efficient R&D capabilities, More than 100 national new drugs have been successfully developed, which constitutes the reasonable production line for the future development of Qilu. A number of technological achievements have obtained the national and provincial scientific & technological progress awards and created good social benefit.
Qilu Pharmaceutical has eight manufacturing sites covering an area of more than 2800,000 ㎡for finished dosage forms, chemical synthesis, genetic-engineering, fermentation, etc. The modern workshops are located in the manufacturing sites where the automatic production lines, key equipments and analytical instruments are imported from the leading suppliers all over the world. Now Qilu Pharmaceutical has been one of the leading global suppliers of Antibiotic APIs and Oncology APIs with huge capacity and good quality.
Qilu pharmaceutical has always been committing itself to providing the high-quality products to the patients and the society. Thanks to the integrated and stringent system of quality control and quality assurance, the company has been the leader of cGMP implementation in China. Its non-sterile APIs (fermentation and chemical synthesis), sterile APIs and comprehensive finished dosages have been respectively approved by USFDA, European Directorate for the Quality of Medicines (EDQM), Therapeutic Goods Administration (TGA) of Australia, Medicines and Healthcare products Regulatory Agency (MHRA) of UK, Medicines Control Council (MCC) of South Africa, and some other national competent authorities.
Qilu Pharmaceutical has an integrated product structure and value chain with over 160 launched products. The company has established a comprehensive domestic and overseas sales network. The global presence has covered North America, Europe, CIS countries, South America, Asia, South Africa and Middle East. The valuable brand of the company has been well built with the quality products and good services.
Dr. Jun Sun
VP, Business Development
Sino-American Pharmaceutical Professionals Association
The Sino-American Pharmaceutical Professionals Association (SAPA) was established in 1993 and is headquartered in the center of the pharmaceutical corridor in New Jersey, USA. Since its inception, SAPA rapidly became one of the most active Chinese professional associations in the US with eight chapters and more than 6,000 members.
SAPA’s members are primarily from large and mid-sized pharmaceutical and biotech companies in the US, with areas of expertise covering almost every aspect of pharmaceutical research and development as well as production.
The organization’s large membership base and their superb scientific and technical abilities has allowed SAPA to be a key source for knowledge exchange on the latest developments in the pharmaceutical, biotechnology, and generic drug industries.
Xiaodong Chen
President (2021-2022)Theramix
zuyong Xia
ceoTopwin pharma
Miss Ocean Chen
BDMTOT BIOPHARM
About TOT BIOPHARM International Company Limited
(HKG:1875)
TOT BIOPHARM is dedicated to developing and commercializing innovative cancer drugs and therapies, striving to build a leading brand of oncology treatments trusted by patients and their families as well as medical professionals.
The Group has in place three major integrated technology platforms:
Therapeutic Monoclonal Antibody and Antibody Drug Conjugates (ADCs) Technology Platform: it integrates research and development (R&D) and production capacities for antibody drugs and ADCs, with the designed production capacity of the commercialization base of biological drugs reaching 16,000L to accommodate high-quality commercialization of drug candidates;
Gene Engineering Based Therapeutics Technology Platform: it integrates anti-tumor immunotherapy, gene therapy and viral therapy and pursues R&D and production of tumor-targeted oncolytic virus products;
Innovative Drug Delivery Technology Platform: We have developed an innovative drug delivery system, including an advanced targeted liposome drug delivery system.
Using these platforms, the Group has studied and developed various anti-tumor drug series, and formed a high quality and comprehensive drug product chain. Currently, the Group has 12 drugs under research and development. On top of developing innovative proprietary drugs, TOT BIOPHARM also draws on its own industry value chain to build a complete industry chain platform that supports from R&D, clinical development to production and marketing. By adopting an open platform business model, it is able to cooperate with biomedical enterprises and third parties in different stages along its industry value chain.
Responsive Web Design powered by 